|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0024485,
umls-concept:C0026769,
umls-concept:C0087111,
umls-concept:C0175668,
umls-concept:C0205329,
umls-concept:C0242618,
umls-concept:C0441833,
umls-concept:C1441506,
umls-concept:C1515021,
umls-concept:C1696465,
umls-concept:C2348042,
umls-concept:C2587213
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1998-1-30
|
|
pubmed:abstractText |
Serial brain MRI is widely used in pilot studies of new agents to monitor treatment efficacy in relapsing-remitting (RR) and secondary progressive (SP) multiple sclerosis (MS). For pilot trials, sample size calculations for the RR subgroup are based on the data from small numbers of patients and separate calculations for the SP subgroup have not been performed. The present study considers these issues.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/9436727-1471866,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9436727-1619410,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9436727-1734325,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9436727-17746394,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9436727-1996879,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9436727-2189084,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9436727-2245307,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9436727-2913928,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9436727-3419593,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9436727-3420246,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9436727-6847134,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9436727-7397479,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9436727-7783875,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9436727-7936181,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9436727-8195804,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9436727-8453453,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9436727-8498825,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9436727-8558143,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9436727-8572668,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9436727-8614497,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9436727-8757002,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9436727-8780061,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9436727-8797541,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9436727-9048709,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9436727-9345468
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0022-3050
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
64
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
50-5
|
|
pubmed:dateRevised |
2010-9-13
|
|
pubmed:meshHeading |
pubmed-meshheading:9436727-Adult,
pubmed-meshheading:9436727-Bias (Epidemiology),
pubmed-meshheading:9436727-Clinical Trials as Topic,
pubmed-meshheading:9436727-Data Interpretation, Statistical,
pubmed-meshheading:9436727-Disease Progression,
pubmed-meshheading:9436727-Drug Monitoring,
pubmed-meshheading:9436727-Female,
pubmed-meshheading:9436727-Follow-Up Studies,
pubmed-meshheading:9436727-Humans,
pubmed-meshheading:9436727-Magnetic Resonance Imaging,
pubmed-meshheading:9436727-Male,
pubmed-meshheading:9436727-Middle Aged,
pubmed-meshheading:9436727-Multiple Sclerosis,
pubmed-meshheading:9436727-Placebos,
pubmed-meshheading:9436727-Recurrence,
pubmed-meshheading:9436727-Reproducibility of Results,
pubmed-meshheading:9436727-Research Design,
pubmed-meshheading:9436727-Severity of Illness Index,
pubmed-meshheading:9436727-Treatment Outcome
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups.
|
|
pubmed:affiliation |
NMR Research Unit, Institute of Neurology, London, UK.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
